Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate

The largest news story this week came from Compass Pathways, as the psilocybin developer announced on Tuesday that it is bringing forward its launch planning by 9-12 months following progress in its second, larger Phase 3 trial (COMP006), which has now completed enrolment, and meetings with FDA. (See Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months.) The news…

Source